Pegasystems Posts Downbeat Q2 Results, Joins Adtran, Dyne Therapeutics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
Organogenesis Holdings Inc ORGO
$2.37
▼ -3.27%
($-0.08)
⬇️ Below Yest. Low
📅 Earnings This Week
Open
$2.48
Prev Close
$2.45
Day Range
$2.30 – $2.48
52W Range
$2.04 – $7.08
Market Cap
$304.96M
P/E (TTM)
112.16
Beta
1.35
EPS (TTM)
$-0.02
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-12-02 |
| Shares Out. | 128,670,000 |
| Website | investors.organogenesis.com ↗ |
| Phone | 13026587581 |
| Employees | 854 |
| Revenue | $37.2M |
| Gross Profit | $37.2M |
| Net Income | -$53.2M |
| Free Cash Flow | $17.1M |
| Total Assets | $520.0M |
| Total Liabilities | $138.6M |
| Equity | $244.6M |
About Organogenesis Holdings Inc
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Organogenesis Holdings Inc is a publicly traded company under the ticker symbol ORGO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-07-01)